The Multifaceted Role of Epicardial and Pericardial Adipose Tissue in Human Health: a Mendelian randomization study

Fashuai Li, Kezhong Ma, Wei Luo, Wenheng Liu, Jidong Zhang, Wenzhong Zhang, Tongjian Zhu, Mengqi Guo, Yan XuResearch Square 2024 · DOI

TL;DR

This study challenges the "fat is always bad" narrative by showing that the adipose tissue surrounding the heart (EPAT) plays a causally protective role against type 2 diabetes, high cholesterol, asthma, and even bipolar disorder. Using Mendelian randomization, researchers identified that EPAT acts as a dynamic endocrine organ, exerting these benefits through specific signaling proteins, immune cells, and metabolites.

What Problem Does This Paper Address?

For years, epicardial adipose tissue (EAT) and pericardial adipose tissue (PAT)—collectively referred to here as EPAT—have been viewed primarily as markers of cardiovascular risk. In adults, high levels of heart fat are often associated with coronary artery disease and heart failure.

However, there is a catch: in infants, this fat resembles "brown fat," which is thermogenic and protective. As we age, it shifts toward a "white fat" phenotype that promotes inflammation. The gap in our knowledge lies in understanding the inherent genetic function of this tissue. Is it a cause of disease, or is the "bad" fat we see in patients simply a protective organ that has gone off the rails? This paper seeks to determine the causal impact of EPAT on a broad spectrum of human health outcomes.

Methods

The researchers employed a sophisticated three-step genetic framework:

  1. Phenome-wide Association Study (PheWAS): They screened thousands of traits to see which ones were statistically linked to genetic variants (SNPs) associated with EPAT volume.
  2. Mendelian Randomization (MR): To move beyond simple correlation, they used MR—a method that uses genetic variants as "natural experiments"—to determine if EPAT volume causes changes in health outcomes. They used 11 independent SNPs as instrumental variables.
  3. Mediation Analysis: Finally, they performed a "look-under-the-hood" analysis to find the biological bridges (mediators) between EPAT and disease, such as plasma proteins, immune cells, and cerebrospinal fluid (CSF) metabolites.

Datasets

The study leveraged massive, high-quality genomic datasets:

  • FinnGen (Freeze 10): Data from 412,181 individuals across 2,405 binary endpoints.
  • UK Biobank: Data from over 500,000 participants, including cardiac magnetic resonance (CMR) imaging to precisely measure fat areas.
  • INTERVAL Study: Used for proteomic data (3,282 plasma proteins) to identify mediators.
  • GWAS Catalog: For data on circulating immune cells and CSF metabolites.

Key Insights and Ideas

  • The Protective Paradigm: Contrary to the "fat is bad" dogma, the genetic predisposition for higher EPAT volume was linked to lower risks for several major diseases. This suggests that the inherent biological function of this tissue is actually cardioprotective and metabolic-friendly.
  • An Endocrine Powerhouse: EPAT isn't just a passive energy reservoir; it’s a "dynamic endocrine organ." It secretes adipokines like adiponectin and adrenomedullin that have anti-inflammatory and anti-atherogenic properties.
  • The Brain-Heart Axis: One of the most surprising findings was the causal link between EPAT and psychiatric health. The study found that EPAT-driven changes in cerebrospinal fluid metabolites could lower the risk of bipolar disorder, suggesting a complex biochemical communication line between heart fat and the central nervous system.
  • Therapeutic Potential: The authors suggest that instead of just trying to "lose" heart fat, a better strategy might be "browning" it—reversing dysfunctional white fat back to its beneficial, brown-fat-like state.

Key Results

The Mendelian randomization analysis revealed several significant protective causal relationships:

  • Type 2 Diabetes: Reduced risk (OR 0.91, $p=0.0009$), partially mediated by the protein LRRN1.
  • High Cholesterol: Reduced risk (OR 0.88, $p=0.04$), mediated by Sex Hormone-Binding Globulin (SHBG).
  • Asthma: Strong protective effect (OR $9.49 \times 10^{-41}$), mediated by specific circulating immune cells (e.g., CD3 on CD45RA- CD4+ T cells).
  • Bipolar Disorder: Reduced risk (OR $3.61 \times 10^{-41}$), mediated by CSF metabolites.
  • Physiological Boosts: EPAT was associated with increased testosterone levels ($\beta=0.25$) and improved Right Ventricular Ejection Fraction (RVEF) ($\beta=7.26$).

Limitations and Future Work

  • Population Specificity: The genetic instruments were primarily derived from individuals of European ancestry, meaning the results might not perfectly generalize to other ethnic groups.
  • Variance Explained: The 11 SNPs used explain only a fraction of the total variance in EPAT volume; other genetic or environmental factors are likely at play.
  • Phenotype Complexity: The study treated EAT and PAT as a single unit (EPAT). Future research should aim to disentangle the distinct (and potentially opposing) roles of these two specific fat depots.
  • Clinical Translation: While MR provides evidence of causality, longitudinal clinical trials and interventional studies are needed to see if "targeting" EPAT can actually treat these diseases in a real-world setting.

Summary updated

Abstract

<title>Abstract</title> Background The influence of epicardial adipose tissue (EAT) on cardiovascular health appears to be modulated by age, metabolic status, and underlying cardiac pathology.The relationship between EAT and pericardial adipose tissue (PAT) remains unclear.The impact of epicardial and pericardial adipose tissue (EPAT) on human health remains unclear. This study aimed to elucidate the causal relationships between EPAT and various health outcomes using large-scale genetic data. Methods We conducted phenome-wide association studies (PheWAS) using data from FinnGen (n = 412,181) and UK Biobank (n &gt; 500,000) to identify EPAT-associated traits. Two-sample Mendelian randomization (MR) analyses were performed to assess causal relationships between EPAT and identified outcomes. Mediation analyses explored potential pathways through which EPAT exerts its effects. Results PheWAS revealed 171 and 181 EPAT-associated traits in FinnGen and UK Biobank, respectively, including cardiovascular, metabolic, psychiatric, and respiratory diseases.EPAT showed protective causal relationships with type 2 diabetes (OR 0.91, 95% CI 0.86 to 0.96, P = 0.0009), high cholesterol (OR 0.88, 95% CI 0.78 to 0.99, P = 0.04), adult-onset asthma (OR 9.49×10⁻⁴¹, 95% CI 8.98×10⁻⁴⁷ to 1.00×10⁻³⁴, P = 9.14×10⁻³⁹), and bipolar disorder (OR 3.61×10⁻⁴¹, 95% CI 2.91×10⁻⁴⁷ to 4.47×10⁻³⁵, P = 1.09×10⁻³⁸). EPAT was also associated with increased testosterone levels (β = 0.25, 95% CI 0.04 to 0.46, P = 0.02) and enhanced right ventricular ejection fraction (β = 7.26, 95% CI 1.34 to 13.18, P = 0.02). Mediation analyses revealed that these effects were partially mediated by various factors, including plasma proteins (e.g., LRRN1 for type 2 diabetes), sex hormone-binding globulin (for high cholesterol), insulin-like growth factor 1 (for testosterone levels), specific immune cells (for asthma), and cerebrospinal fluid metabolites (for bipolar disorder). Conclusion This study reveals a complex and multifaceted role of EPAT in human health, extending beyond its established role in cardiovascular disease. Our findings indicate that EPAT could be a promising therapeutic target for multiple diseases. Potential drug development strategies include reversing harmful EPAT to a beneficial state or maintaining its beneficial properties long-term.
BibTeX
@inproceedings{li2024multifaceted,
  author = {Fashuai Li and Kezhong Ma and Wei Luo and Wenheng Liu and Jidong Zhang and Wenzhong Zhang and Tongjian Zhu and Mengqi Guo and Yan Xu},
  title = {{The Multifaceted Role of Epicardial and Pericardial Adipose Tissue in Human Health: a Mendelian randomization study}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-5285851/v1},
}
Figure